Scott S Conner

US Patent:

7405305, Jul 29, 2008

Filed:

Mar 5, 2003

Appl. No.:

10/506029

Inventors:

Pamela Ann Albaugh - Carlsbad CA, US
Jochen Ammenn - Hamburg, DE
Timothy Paul Burkholder - Carmel IN, US
Joshua Ryan Clayton - Cicero IN, US
Scott Eugene Conner - Indianapolis IN, US
Brian Eugene Cunningham - Martinsville IN, US
Thomas Albert Engler - Indianapolis IN, US
Kelly Wayne Furness - Avon IN, US
James Robert Henry - Indianapolis IN, US
Sushant Malhotra - Indianapolis IN, US
Mark Joseph Tebbe - Indianapolis IN, US
Guoxin Zhu - Noblesville IN, US
YiHong Li - Carmel IN, US
Brian Raymond Berridge - Greenfield IN, US
Charles Edward Ruegg - Indianapolis IN, US
John Morris Sullivan - Greenfield IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07D 209/12
C07D 207/24
C07D 211/06

US Classification:

548469, 548547, 546184

Abstract:

The present invention provides kinase inhibitors of Formula (I).

US Patent:

7696248, Apr 13, 2010

Filed:

Nov 7, 2006

Appl. No.:

12/093054

Inventors:

Jianke Li - Hamden CT, US
Scott Eugene Conner - Indianapolis IN, US
Guoxin Zhu - Shanghai, CN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31/195
C07C 229/00

US Classification:

514563, 562450

Abstract:

The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.